About Pharos iBio
Pharos iBio is a company based in Anyang (South Korea) founded in 2016. Pharos iBio has raised $15.86 million across 1 funding round from investors including Company K Partners, UTC Investment and Solidus Investment. The company has 32 employees as of December 31, 2024. Pharos iBio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Anyang, South Korea
- Employees 32 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Pharos Ibio Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$7.16 M (USD)-19.21as on Dec 31, 2024
-
EBITDA
-$8 M (USD)-25.09as on Dec 31, 2024
-
Total Equity Funding
$15.86 M (USD)
in 1 rounds
-
Latest Funding Round
$15.86 M (USD), Series C
Jun 23, 2021
-
Investors
Company K Partners
& 6 more
-
Employee Count
32
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pharos iBio
Pharos iBio is a publicly listed company on the KRX with ticker symbol 388870 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Pharos iBio
Pharos iBio has successfully raised a total of $15.86M through 1 strategic funding round. The most recent funding activity was a Series C round of $15.86 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pharos iBio
Pharos iBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Company K Partners, UTC Investment and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in tech startups
|
Locked | Locked | Locked | |
|
Venture capital and private equity investment firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Pharos iBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharos iBio
Investment portfolio details for Pharos iBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pharos iBio
Detailed financials for Pharos iBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharos Ibio Comparisons
Peer comparison for Pharos iBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pharos iBio
Pharos iBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Pharos iBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharos Ibio
Complete news archive for Pharos iBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharos iBio
Pharos iBio was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Pharos iBio is headquartered in Anyang, South Korea. It is registered at Anyang, Gyeonggi-do, South Korea.
Jeonghyeok Yoon is the current CEO of Pharos iBio.
Pharos iBio is a funded company, having raised a total of $15.86M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Pharos iBio is 32.
Pharos iBio was established in 2016 in Anyang, South Korea, within the biotechnology sector. Focus is placed on developing therapeutics targeting oncology and rare diseases. The pipeline includes drug candidates like PHI-101-001 for acute myeloid leukemia, PHI-101-002 for ovarian cancer, PHI-101-003 for metastatic triple-negative breast cancer, and PHI-401 for ALK-mutated lung adenocarcinoma, along with other programs in progress. Operations center on advancing these candidates through clinical development.
Pharos iBio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Pharos iBio is publicly traded on KRX under the ticker symbol 388870.
Pharos iBio has 7 investors. Key investors include Company K Partners, UTC Investment, Solidus Investment, Intops Investment, and KBD Capital.
The ticker symbol of Pharos iBio is 388870 on KRX.